Non-alcoholic Steatohepatitis Treatment Market Set to Surge at 28.0% CAGR
The global non-alcoholic steatohepatitis (NASH) treatment market is poised for unprecedented growth over the next decade. Valued at USD 7.70 billion in 2024 , the market is projected to surge to USD 90.97 billion by 2034 , registering an impressive compound annual growth rate (CAGR) of 28.0% during the 2024–2034 period. This surge is primarily driven by the rising global prevalence of NASH, a severe form of fatty liver disease , and the rapid development of new therapies targeting liver fibrosis and inflammation. NASH is a progressive liver disease that occurs in individuals who consume little or no alcohol but experience liver inflammation and damage due to fat accumulation. Without timely intervention, NASH can progress to cirrhosis, liver failure, or hepatocellular carcinoma (HCC). The disease is closely associated with metabolic syndrome, obesity, type 2 diabetes, and dyslipidemia — all of which are rising globally. Market Overview Non-alcoholic steatohepatitis,...